THE PRESENT INVENTION IS DIRECTED TO A PHARMACEUTICAL COMPOSITION COMPRISED OF ONE OR MORE SGLT-2 INHIBITOR COMPOUND(S) IN COMBINATION WITH ONE OR MORE THERAPEUTIC AGENTS WHICH IS SUITABLE FOR THE TREATMENT OF METABOLIC DISORDERS INCLUDING TYPE 1 DIABETES MELLITUS, TYPE 2 DIABETES MELLITUS, IMPAIRED GLUCOSE TOLERANCE, HYPERGLYCEMIA, POSTPRANDIAL HYPERGLYCEMIA, OVERWEIGHT, OBESITY, INCLUDING CLASS I OBESITY, CLASS II OBESITY, CLASS III OBESITY, VISCERAL OBESITY AND ABDOMINAL OBESITY, AND METABOLIC SYNDROME.